| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Endogenous metabolite; mannose-6-phosphate isomerase; phosphomannomutase; GDP-mannose pyrophosphorylase; mannose transporters; FimH adhesin (bacterial). D-Mannose is phosphorylated by hexokinase to mannose-6-phosphate, which is converted to fructose-6-phosphate or GDP-mannose for N-linked glycosylation and GPI anchor synthesis.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
As a labeled metabolite, D-Mannose-13C-2 exhibits the same intrinsic biological activity as unlabeled D-mannose. It is taken up by cells via mannose transporters and incorporated into glycoproteins and glycolipids. It supports metabolic labeling of cellular glycans. At high concentrations (10-25 mM), it can inhibit cell proliferation and induce apoptosis in some cell types. |
| ln Vivo |
In vivo, D-Mannose-13C-2 is used for metabolic tracing of mannose metabolism and glycosylation. Following administration, it is incorporated into tissue glycoproteins and glycolipids. D-Mannose supplementation has shown benefits in urinary tract infections by inhibiting bacterial adhesion and in congenital disorders of glycosylation.
|
| Enzyme Assay |
For mannose-6-phosphate isomerase assays, incubate with mannose-6-phosphate and measure fructose-6-phosphate by coupled enzyme assay. For GDP-mannose pyrophosphorylase, measure GDP-mannose by HPLC. Analyze products by LC-MS/MS to quantify 13C enrichment in mannose metabolites.
|
| Cell Assay |
For metabolic labeling, culture cells with D-Mannose-13C-2 (1-25 mM) for 24-72 hours. Extract glycoproteins and analyze by LC-MS/MS for 13C enrichment in mannose residues. For glycosylation studies, assess N-linked glycosylation by Western blot or lectin binding.
|
| Animal Protocol |
For in vivo metabolic tracing, mice receive D-Mannose-13C-2 (100-500 mg/kg) via oral gavage or intraperitoneal injection. Collect liver, brain, and kidney at 0-24 hours. Extract glycoproteins and analyze by LC-MS/MS for 13C enrichment in mannose residues. For infection studies, supplement mannose and quantify bacterial burden.
|
| References |
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
[2]. Genovese C, et al. Effects of a new combination of plant extracts plus d-mannose for the management of uncomplicated recurrent urinary tract infections. J Chemother. 2018 Apr;30(2):107-114. |
| Additional Infomation |
Aldose-hexose is a hexose with a (potential) aldehyde group at one end. It is both an aldose and a hexose. D-mannose has been reported in peas (Pisum sativum), and relevant data are available. It is a major energy source for organisms. It exists naturally, in a free state in fruits and other parts of plants. It is used medicinally to replenish body fluids and nutrients. See also: Polydextrose (note moved to); D-allose (note moved to); D-mannose (note moved to)... See more...
|
| Molecular Formula |
C6H12O6
|
|---|---|
| Molecular Weight |
180.155882835388
|
| Exact Mass |
181.066
|
| CAS # |
101615-89-8
|
| Related CAS # |
D-Mannose;3458-28-4
|
| PubChem CID |
24749
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.6±0.1 g/cm3
|
| Index of Refraction |
1.573
|
| LogP |
-2.9
|
| tPSA |
118
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
12
|
| Complexity |
138
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[C@@H]1(O)C(CO)OC(O)C(O)C1O
|
| InChi Key |
GZCGUPFRVQAUEE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H12O6/c7-1-3(9)5(11)6(12)4(10)2-8/h1,3-6,8-12H,2H2
|
| Chemical Name |
2,3,4,5,6-pentahydroxyhexanal
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5506 mL | 27.7531 mL | 55.5062 mL | |
| 5 mM | 1.1101 mL | 5.5506 mL | 11.1012 mL | |
| 10 mM | 0.5551 mL | 2.7753 mL | 5.5506 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.